<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Halozyme Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc</link>
<description>Latest news and press releases for Halozyme Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/halozyme-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357c1878dffbe2df0f99d0.webp</url>
<title>Halozyme Therapeutics Inc</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc</link>
</image>
<item>
<title>Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/russell-investments-canada-limited-announces-monthly-distributions-for-exchange-traded-fund-series-etf-series-and-exchange-traded-funds-etfs-3</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/russell-investments-canada-limited-announces-monthly-distributions-for-exchange-traded-fund-series-etf-series-and-exchange-traded-funds-etfs-3</guid>
<pubDate>Tue, 14 Apr 2026 20:00:00 GMT</pubDate>
<description>TORONTO, April 14, 2026--Russell Investments Canada Limited ("Russell Investments Canada") today announced cash distributions for the ETF Series and ETFs for the months of April, May, and June. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date</description>
</item>
<item>
<title>Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercontm-technology</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercontm-technology</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary,</description>
</item>
<item>
<title>Halozyme Appoints David Ramsay as Interim Chief Financial Officer</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-appoints-david-ramsay-as-interim-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-appoints-david-ramsay-as-interim-chief-financial-officer</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been</description>
</item>
<item>
<title>Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/breakout-ventures-launches-fund-iii-with-dollar114m-to-continue-building-the-future-powered-by-science</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/breakout-ventures-launches-fund-iii-with-dollar114m-to-continue-building-the-future-powered-by-science</guid>
<pubDate>Tue, 10 Mar 2026 11:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 10, 2026--Breakout Ventures today announced the close of its $114M Fund III.</description>
</item>
<item>
<title>U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/us-fda-approves-tecvaylir-in-combination-with-darzalex-faspror-for-relapsedrefractory-multiple-myeloma-26</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/us-fda-approves-tecvaylir-in-combination-with-darzalex-faspror-for-relapsedrefractory-multiple-myeloma-26</guid>
<pubDate>Fri, 06 Mar 2026 13:00:00 GMT</pubDate>
<description>Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy.1</description>
</item>
<item>
<title>Russell Investments Expands Canadian ETF Lineup With Five New Offerings</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/russell-investments-expands-canadian-etf-lineup-with-five-new-offerings</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/russell-investments-expands-canadian-etf-lineup-with-five-new-offerings</guid>
<pubDate>Wed, 18 Feb 2026 14:30:00 GMT</pubDate>
<description>TORONTO, February 18, 2026--Russell Investments Canada Limited today announced the launch of five new exchange-traded funds (ETFs) on the Toronto Stock Exchange (TSX), further expanding its Canadian ETF platform and giving investors additional cost-effective options across core fixed income and equity allocations.</description>
</item>
<item>
<title>HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-reports-full-2025-record-210100788</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-reports-full-2025-record-210100788</guid>
<pubDate>Tue, 17 Feb 2026 21:01:00 GMT</pubDate>
<description>Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities.</description>
</item>
<item>
<title>Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-report-fourth-quarter-full-210500387</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-report-fourth-quarter-full-210500387</guid>
<pubDate>Tue, 10 Feb 2026 21:05:00 GMT</pubDate>
<description>Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading.</description>
</item>
<item>
<title>Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-raises-2025-revenue-estimates-113000667</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-raises-2025-revenue-estimates-113000667</guid>
<pubDate>Wed, 28 Jan 2026 11:30:00 GMT</pubDate>
<description>Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year financial guidance. The Company also announced it acquired Surf Bio, Inc. ("Surf Bio"), a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in December 2025.</description>
</item>
<item>
<title>Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-host-investor-conference-call-210500669</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-host-investor-conference-call-210500669</guid>
<pubDate>Tue, 20 Jan 2026 21:05:00 GMT</pubDate>
<description>Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET.</description>
</item>
<item>
<title>Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-announces-global-collaboration-and-license-agreement-takeda-develop-and</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-announces-global-collaboration-and-license-agreement-takeda-develop-and</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumabSAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme</description>
</item>
<item>
<title>Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-and-skye-bioscience-announce-global-collaboration-and-license-agreement-0</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-and-skye-bioscience-announce-global-collaboration-and-license-agreement-0</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimabSAN DIEGO, Jan. 5, 2026 /PRNewswire/</description>
</item>
<item>
<title>Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/huonslab-announces-submission-of-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/huonslab-announces-submission-of-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm</guid>
<pubDate>Mon, 22 Dec 2025 14:00:00 GMT</pubDate>
<description>PANGYO, South Korea, December 22, 2025--Huonslab files BLA for HYDIZYME™, targeting MFDS approval in 2026 for its recombinant human hyaluronidase using HyDIFFUZE™.</description>
</item>
<item>
<title>U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/us-fda-approves-rybrevant-fasprotm-amivantamab-and-hyaluronidase-lpuj-co-formulated</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/us-fda-approves-rybrevant-fasprotm-amivantamab-and-hyaluronidase-lpuj-co-formulated</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.</description>
</item>
<item>
<title>Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/bench-international-announces-appointment-of-jim-lang-to-the-board-of-directors-of-halozyme-therapeutics-1</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/bench-international-announces-appointment-of-jim-lang-to-the-board-of-directors-of-halozyme-therapeutics-1</guid>
<pubDate>Wed, 17 Dec 2025 13:30:00 GMT</pubDate>
<description>Bench International today announced the appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on advancing innovative drug delivery technologies that improve how medicines are delivered to patients worldwide.</description>
</item>
<item>
<title>Jim Lang Elected to Halozyme's Board of Directors</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/jim-lang-elected-halozymes-board-directors-2025-12-08</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/jim-lang-elected-halozymes-board-directors-2025-12-08</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of</description>
</item>
<item>
<title>Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-wins-preliminary-injunction-against-mercks-keytruda-sc-germany-2025-12-04</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-wins-preliminary-injunction-against-mercks-keytruda-sc-germany-2025-12-04</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for</description>
</item>
<item>
<title>Halozyme to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-participate-8th-annual-evercore-healthcare-conference-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-participate-8th-annual-evercore-healthcare-conference-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief</description>
</item>
<item>
<title>Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-completes-acquisition-elektrofi-expanding-breadth-offerings-drug-delivery</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/halozyme-completes-acquisition-elektrofi-expanding-breadth-offerings-drug-delivery</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly</description>
</item>
<item>
<title>Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab</title>
<link>https://6ix.com/company/halozyme-therapeutics-inc/news/merus-and-halozyme-enter-global-collaboration-and-license-agreement-develop</link>
<guid isPermaLink="true">https://6ix.com/company/halozyme-therapeutics-inc/news/merus-and-halozyme-enter-global-collaboration-and-license-agreement-develop</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company</description>
</item>
</channel>
</rss>